According to Data Bridge Market Research new Market report “Global Tumour Ablation Market, By Type (Tumour Ablation Systems (Radio Frequency Ablation, Microwave Ablation, HIFU, Laser Ablation, Cryoablation), Image Guidance Products, Accessories), By Cancer Type (Liver, Lings, Kidney, Brain, Bone, Pancreas, Breast, Others), By End-User (Hospitals, Oncology Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) - Trends and Forecast to 2022”, has accounted for USD 1.7 billion in 2015, and is expected to reach USD 2.9 billion by 2022, growing at a CAGR 8.2% during the forecast period 2016 to 2022.
The global tumour ablation market is expected to grow, owing to factors such as rising cancer incidence, increased focus on treatment of breast cancer, better reimbursement scenarios, shift towards value based reimbursements and continuous development in ablation technology. The ablation technology has an upper edge on chemotherapy and other oncology therapeutics. However ablation technology can only be used to treat tumours with size less than 3cm, owing to the healthy tissue damage caused by it. With the advent of guidance mechanisms such as ultrasounds and MRI the accuracy of the treatment has increased significantly in the past 5 years.
The ablation technology involves no surgery, an electrode is percutaneously inserted in the cancerous tissue and with the help of thermal energy the tissue is destroyed. The precision in placement of the electrode and the controlling of the temperature can be monitored using a controller and a image guidance system. In the last decade promising results have been delivered by using ablation technology which is fuelling the growth of this market.
The trend in oncology treatment is moving towards multi-specialty tumour boards collaborating into similar treatment pathways. Professionals from interventional cardiology, surgical oncology, urology, thoracic surgeries, medical oncology, radiation oncology and, breast surgeries are collaborating using ablation technology to treat cancer. This is expected to widespread the usage of this technology and fuel the market growth in the forecast years.
The global tumour ablation market is segmented based on product types, cancer types, end-user and geography.
The global tumour ablation market is segmented into 3 type’s ablation systems, image guidance products and accessories. The ablation systems dominates the market and is further segmented based on product type into microwave ablation (coretherm thermotherapy devices and prolieve thermotherapy devices), radiofrequency ablation (RFA) ((temperature controlled devices, fluid cooled, catheter manipulation systems), high intensity focused ultrasound (HIFU), laser ablation and cryoablation. All ablation techniques are percutaneous except HIFU which is administered transcutaneously.
In 2015, RFA dominate the market owing to larger application area and a longer tenure, however the increasing acceptance of microwave ablation may cause a decline in RFA revenues by 2022. Microwave ablation is a more targeted approach where larger ablation zones are formed hence reducing heat caused damage to healthy tissues. Also the usage of laser ablation in brain cancer and prostate cancer is expected to drive the growth of this segment. HIFU is the brand new technology which has a advantage over RFA, such as decreased recurrence rates from 17% to 2% as per CDC data, a decreased ablation time and most importantly almost 50% cost effective than its counterpart.
On the basis of cancer types treated using ablation devices the market is segmented into liver, lings, kidney, brain, bone, pancreas, breast and, other cancer types. In 2015, the liver cancer treatment is the most used application for ablation devices; however in the forecast period market potential for breast cancer is expected to be highest and is going to dominate the market by 2022.
Based on end-user the global tumour ablation market is segmented into hospitals, oncology clinics and others. In 2015, hospitals segment dominate the market with more than 65% market share. Oncology clinics is expected to grow at the highest CAGR of 10.3% in the forecast period, owing to development of less time consuming technologies like HIFU increasing in acceptance which will increase the outpatient surgeries which is already trending in global healthcare.
Based on geography the global tumour ablation market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. In 2016, Europe is expected to dominate the market with 36.7% market share, owing to the large incidence of cancer patients in this region coupled with good reimbursements.
Asia Pacific is expected to grow at the highest CAGR 10.3% in the forecast period owing to factors such as medical tourism, increasing cancer prevalence and, the increasing acceptance of ablation technologies in China, India, South Korea, Hong Kong and ASEAN countries. Developing markets such as India, China, Brazil and Russia are lucrative market where major players are engaging into marketing and improvement of tumour ablation technologies.
The tumour ablation market’s major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Some examples of recent strategies/developments are: On January, 2016 Medtronic acquired OsteoCool RF Ablation System from Baylis Medical and received its FDA approval, December, 2015 DFINE, Inc. launched Long SpineStar ablation system, January 2015, Medtronic acquired Covidien to strengthen its leadership in medical devices industry among others. The report includes market shares of tumor ablation market for global, Europe, North America, Asia Pacific and Rest of the World.
In 2015, Medtronic has dominated the global tumour ablation market. Some of the other key players operating in this market are Galil Medical, Inc., Perseon Corporation, NeuWave Medical, Inc., Koninklijke Philips N.V., INTIO Inc., Mermaid Medical A/S, SonaCare Medical, LLC, DFINE, Inc., Misonix, Inc., BVM Medical Limited, AngioDynamics, Inc., COMSOL Inc., Boston Scientific Corporation, EDAP TMS S.A. and, HealthTronics, Inc. among other companies.
Global Radiotherapy Market, By Therapy (Beam Radiotherapy (IGRT, IMRT, VMAT, Tomotherapy, 3D CRT, Proton Beam, Stereotactic), Brachytherapy (LDR, HDR), Systemic Radiotherapy), By Product Type (Cyberknife, Gammaknife, Linac, Proton Beam, Systemic Radiotherapy, Seeds, Afterloaders), By Indication (Prostate & Breast Cancer)), By Geography (North America, Europe, Asia Pacific, South America, Rest of the World) – Trends and Forecast to 2022
Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022
Visit Data Bridge Blog@ http://databridgemarketresearch.com/blog/
Global Tumor Ablation Market – Industry Trends and Forecast to 2026
Tumor Ablation Market Rising at 13.80% CAGR Due to Surging Incidences of Cancer
Tumour Ablation Market is Poised to Grow At 8.2% Till 2024
Global Tumor Ablation Market: Awareness Programs and Improvement of Cancer Treatment Service Initiatives Improving the Growth of Tumor Ablation